

# Spotlight on Key Sessions You Cannot Miss at Ophthalmic Drugs

*SMI's Presents Europe's Leading Ophthalmic Conference, Ophthalmic Drugs*

LONDON, UNITED KINGDOM, September 11, 2017 /EINPresswire.com/ -- Are you aware the ophthalmic market is expected to reach \$21 billion by the year 2022? Ocular disease therapy has seen a surge in innovation in areas ranging from glaucoma to macular degeneration and diabetic retinopathy.

Featuring an exceptional line-up of keynote speakers from industry leading organisations, Europe's leading conference on Ophthalmic Drugs arrives at the perfect time to discuss the latest approaches in key areas such as ocular diseases, drug delivery, pre-clinical and clinical trials, computer technologies and therapies for diabetic macular oedema. Agenda highlights will include a [spotlight](#) on therapies for glaucoma, diabetes and approaches to drug release and delivery.

## Spotlight

- Minimally Invasive Glaucoma Surgery for various glaucoma treatments will address the use of conjugate drugs and a new prostaglandin drug product co-developed by Santen, called 'Omidenepag Isopropyl.' - Naj Sharif, Executive Director in R&D, Head, Global Alliances & External Research, Santen Inc

- Non-Proliferative Diabetic Retinopathy. The therapies and solutions for this disease will be examined, including light and laser therapy and oral therapies as well as the use of steroids. - Victor Chong, Global Head of Ophthalmology, Boehringer Ingelheim

- Nanotechnology, and how this can be utilised to develop extended release therapies for glaucoma, cataract, AMD and DME indications. - Tomas Navratil, Senior Vice President, Development, Envisia Therapeutics

- Diabetic Macular Oedema (DMO) is a leading cause of vision loss in the working-age population worldwide. We will discuss the challenges encountered during clinical development and market access for a revolutionary 36 month intra-vitreous steroid implant. There will also be an emphasis on the importance of 'Real World Data'. - Steve Morris, VP, Medical Director, UK and Head of Medical Affairs EU, Alimera Sciences

Further information is available at: [www.ophthalmicdrugs.com/ein](http://www.ophthalmicdrugs.com/ein)

For those looking to attend there is currently a £200 [early-bird](#) saving!

SMi Presents the Launch of...

Ophthalmic Drugs

Date: 28th – 29th November 2017

Location: Kensington, London

Website: [www.ophthalmicdrugs.com/ein](http://www.ophthalmicdrugs.com/ein)

Sponsored by: Leica Microsystems | Experimentica

---end---

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: [psolanki@smi-online.co.uk](mailto:psolanki@smi-online.co.uk)

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Pav Solanki  
Mr.  
2078276048  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.